CytoDyn (CYDY) announced positive results from its preclinical studies with SMC Laboratories, SMC. The three studies demonstrated statistically ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today ...

Learn more about whether Avient Corporation or Olin Corporation is a better investment based on AAII's A+ Investor grades, ...

The European Court of Human Rights has ruled that Italy violated the right to life of Italians living in a toxic-waste ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic ...

Learn more about whether The Chemours Company or Olin Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Olin (NYSE:OLN – Get Free Report) had its price objective reduced by investment analysts at KeyCorp from $50.00 to $40.00 in ...

Olin (NYSE:OLN – Free Report) had its price objective cut by Barclays from $43.00 to $34.00 in a research note released on ...

The flavonoid silymarin and one of its structural components, silibinin, are substances with documented hepatoprotective properties. Their mechanisms of action are still poorly understood. However ...